Symbiotix' lead clinical candidate, Polysaccharide A (PSA), is the first molecule to emerge from the microbiome and the $2.3 million NIH award enables the completion of key translational studies and production of material needed to take into human clinical trials as a novel treatment for multiple sclerosis (MS), said Prof. Lloyd Kasper, Professor of Medicine, Microbiology and Immunology at Geisel School of Medicine at Dartmouth College, and Co-Founder of Symbiotix.
PSA is a first-in-class oral therapy that works through a novel mechanism of action related to activation of regulatory T cells, which exert an anti-inflammatory effect through the production of IL-10.
"Current FDA-approved therapies for multiple sclerosis offer only partial benefit for reduction of relapses and time to disability.
However, all of these FDA-approved treatments have side effects some of which can be rather profound," said Prof. Kasper
"We are developing PSA as a safe and effective new oral therapy for the over 500,000 US patients with multiple sclerosis.